Altamira Therapeutics Expands Bentrio Distribution to Scandinavia

Altamira Therapeutics Expands Bentrio Distribution Agreement

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (NASDAQ: CYTO) has announced an extension of its exclusive distribution agreement with Pharma Nordic AS, which will now also cover Sweden and Denmark. This decision comes on the heels of a successful launch of the Bentrio nasal spray in Norway, where the product has been well-received this year.

Bentrio's Role in Allergic Rhinitis Management

Bentrio is a drug-free nasal spray specially formulated to prevent and treat allergic rhinitis. Its introduction into the Swedish and Danish markets marks a significant step forward in providing effective treatment alternatives for patients suffering from this condition. Pharma Nordic plans to leverage its successful strategies in Norway to roll out Bentrio in these two new regions next year.

Market Expansion Justification

Thomas Meyer, Chairman and CEO of Altamira Medica, expressed confidence in this collaboration, stating, “We have been very pleased and impressed by Pharma Nordic’s market launch activities and success in Norway. It is therefore of mutual interest to expand the geographical scope of our collaboration.” This reflects the potential for Bentrio to become a key player in the field of allergic rhinitis management within Scandinavia.

About Bentrio and Its Unique Formulation

Bentrio stands out as an over-the-counter nasal spray designed for personal protection against airborne allergens. Its innovative formulation eliminates the need for drugs or preservatives, providing a viable option for those seeking safe treatment alternatives. Upon administration, Bentrio creates a protective gel layer in the nasal cavity, minimizing exposure to airborne irritants and pathogens.

Clinical Trials and Efficacy

Clinical trials have validated the effectiveness of Bentrio, particularly the NASAR study, which involved 100 participants with seasonal allergic rhinitis. Results highlighted a statistically significant reduction in Total Nasal Symptom Scores (rTNSS), showcasing the product's superior efficacy compared to saline nasal sprays. Participants reported notable improvements in their quality of life, reinforcing Bentrio's potential in alleviating allergic symptoms.

About Altamira Therapeutics

Founded in 2003, Altamira Therapeutics operates at the forefront of biomedical innovation. The company specializes in developing peptide-based nanoparticle technologies, aiming to enhance RNA delivery to extrahepatic tissues through its platforms OligoPhore™ and SemaPhore™. Two flagship siRNA programs for treating KRAS-driven cancers and rheumatoid arthritis are currently in preclinical development, highlighting Altamira's commitment to advancing healthcare solutions.

Commercial Strategy and Future Goals

Additionally, Altamira maintains a 49% stake in Altamira Medica AG, which oversees the commercial distribution of Bentrio. The company is actively pursuing partnerships to maximize the potential of its pipeline, while also seeking avenues to divest from non-core legacy assets. This strategic approach will allow Altamira to focus on its growth opportunities in the biopharmaceutical sector.

About Pharma Nordic

Pharma Nordic AS, based in Norway, holds licenses for over-the-counter medicines and medical technical equipment across the Nordic regions. Its collaboration with Altamira signifies the company’s ambition to introduce innovative healthcare products to market, ensuring patients have access to effective therapeutic options.

Frequently Asked Questions

What is Bentrio used for?

Bentrio is an over-the-counter nasal spray used for the prevention and treatment of allergic rhinitis, designed to protect against airborne allergens and viruses.

Who is distributing Bentrio in Scandinavia?

Pharma Nordic AS is the distributor for Bentrio in Scandinavia, having expanded their agreement with Altamira Therapeutics to include Sweden and Denmark.

What are the benefits of using Bentrio?

Bentrio is drug-free and preservative-free, offering a safe and effective alternative for individuals suffering from allergic rhinitis, as validated by clinical studies demonstrating its efficacy.

When is Bentrio expected to launch in Sweden and Denmark?

Pharma Nordic plans to introduce Bentrio to the Swedish and Danish markets next year following the successful launch in Norway.

What are Altamira Therapeutics' main areas of focus?

Altamira Therapeutics focuses on developing nanoparticle technologies for RNA delivery and has ongoing projects targeting treatments for certain cancers and rheumatoid arthritis.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.